dietmar berger news - Search News

Gilead appoints Dietmar Berger

Reuters on MSN · 15h

Gilead appoints Sanofi official Dietmar Berger as next chief medical officer

Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who is preparing to leave early next year.Berger, who will join on Jan.

YAHOO!Finance · 18h

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead’s senior leadership team.

MarketWatch · 17h

Gilead Sciences Names Sanofi's Berger as Next Chief Medical Officer

Gilead Sciences named former Sanofi executive Dietmar Berger as chief medical officer, effective Jan. 2, succeeding Merdad Parsey.

Business Insider · 18h

Gilead appoints Dietmar Berger as Chief Medical Officer

Gilead (GILD) announced that Dietmar Berger will join the company on January 2, 2025, as Chief Medical Officer and will become a member of

FierceBiotech7h

Gilead's Daniel O'Day relishes Dietmar Berger reunion as cancer specialist agrees to join from Sanofi

Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...

ENDPOINTS NEWS4h

Gilead names Dietmar Berger CMO as it eyes R&D reset

Gilead Sciences names Sanofi's Dietmar Berger as new CMO, replacing Merdad Parsey amid challenging year marked by setbacks ...

The Pharma Letter4h

Gilead Sciences names new CMO

US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...

The American Journal of Managed Care1d

Rare Blood Disease Innovations Address Unmet Needs, According to ASH Data

Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & ...

GlobalData on MSN4d

Sanofi’s Phase III trial of rilzabrutinib for thrombocytopenia meets endpoint

Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune ...

3d

Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients

ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patientsNew analysis from the IMROZ phase 3 ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results